Pressure BioSciences (OTCQB: PBIO), a leader in the
development and sale of high pressure-based instruments, consumables, and
related services for the global life sciences and other industries worldwide,
today announced the establishment of a Center of Excellence (“CoE”) at Dr.
Christine Vogel’s laboratory at New York University’s Center for Genomics and
Systems Biology. As a CoE, the lab will have free use of PBIO’s Barocycler
2320EXTREME (“2320EXT”) primary instrument system through the end of 2020. In
addition, the collaboration will offer early access to new, modified, and/or
improved versions of the 2320EXT instrument and its associated applications, as
well as the opportunity to work closely with PBIO’s senior science and
engineering staff on new developments in its pressure-based technology
platforms. “We are pleased to have the opportunity to collaborate with
Professor Christine Vogel, a well-respected thought leader in proteomics,” PBIO
Chief Commercial Officer Dr. Bradford A. Young said in the news release. “We
believe the 2320EXT has the potential to support and advance the exciting work
that she and her team already have underway at the GSB Center. We further
believe that the added exposure received by the PCT platform during the
collaboration period will increase awareness of the benefits of our
pressure-based technologies in helping to provide scientists with superior
proteomic analyses. We believe this added awareness should result in increased
products and services revenue in 2019 and beyond.”
To view the full press release, visit http://ibn.fm/eyAho
About Pressure BioSciences Inc.
Pressure BioSciences, Inc. (OTCQB: PBIO) is a leader in the
development and sale of innovative, broadly enabling, pressure-based solutions
for the worldwide life sciences industry. The company’s products are based on
the unique properties of both constant (i.e., static) and alternating (i.e.,
pressure cycling technology, or “PCT”) hydrostatic pressure. PCT is a patented
enabling technology platform that uses alternating cycles of hydrostatic
pressure between ambient and ultra-high levels to safely and reproducibly
control bio-molecular interactions (e.g., cell lysis, biomolecule extraction).
PBIO’s primary focus is in the development of PCT-based products for biomarker
and target discovery, drug design and development, biotherapeutics
characterization and quality control, soil & plant biology, forensics, and
counter-bioterror applications. Additionally, major new market opportunities
have emerged in the use of its pressure-based technologies in the following
areas: (1) the use of its recently acquired PreEMT technology from BaroFold,
Inc. to allow entry into the biologics contract research services sector, and
(2) the use of its recently-patented, scalable, high-efficiency, pressure-based
Ultra Shear Technology (“UST”) platform to (i) create stable nanoemulsions of
otherwise immiscible fluids (e.g., oils and water) and to (ii) prepare higher
quality, homogenized, extended shelf-life or room temperature stable low-acid
liquid foods that cannot be effectively preserved using existing non-thermal
technologies. For more information, visit the company’s website at www.PressureBiosciences.com.
NOTE TO INVESTORS: The latest news and updates
relating to PBIO are available in the company’s newsroom at http://ibn.fm/PBIO
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
